• LAST PRICE
    12.3100
  • TODAY'S CHANGE (%)
    Trending Up1.8300 (17.4618%)
  • Bid / Lots
    11.0100/ 1
  • Ask / Lots
    17.6100/ 2
  • Open / Previous Close
    10.3000 / 10.4800
  • Day Range
    Low 10.3000
    High 12.5200
  • 52 Week Range
    Low 6.8789
    High 23.5800
  • Volume
    19,868
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 10.48
TimeVolumeANTX
10:02 ET20010.51
10:04 ET72110.66
10:06 ET111010.6735
10:18 ET20410.55
10:56 ET10010.645
10:58 ET100010.645
12:10 ET86611
12:42 ET10010.995
01:42 ET233311.04
01:47 ET99910.9359
01:49 ET10011.29
01:58 ET10011.33
02:27 ET10011.33
02:56 ET10011.42
03:21 ET10011.5
03:33 ET10011.45
03:39 ET137511.49
03:44 ET114811.81
03:48 ET10011.72
03:51 ET10012.195
03:53 ET10012.2
03:55 ET119611.97
03:57 ET15712.03
04:00 ET89612.31
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANTX
AN2 Therapeutics Inc
203.3M
0.0x
---
United StatesOLMA
Olema Pharmaceuticals Inc
200.7M
-1.9x
---
United StatesTNYA
Tenaya Therapeutics Inc
207.3M
-1.1x
---
United StatesACIU
AC Immune SA
195.5M
-2.5x
---
United StatesOMIC
Singular Genomics Systems Inc
194.2M
-2.2x
---
United StatesGOSS
Gossamer Bio Inc
216.4M
-0.8x
---
As of 2023-01-26

Company Information

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic and progressive infectious disease caused by bacteria, mycobacteria. Epetraborole has antimycobacterial activity through the inhibition of an essential and universal step in bacterial protein synthesis. Its mechanism of action is enabled by boron chemistry, which is the Company’s core technology approach. Epetraborole is under development in a pivotal Phase II/III clinical trial as a once-daily, oral treatment for patients with NTM lung disease with an initial focus on treatment-refractory Mycobacterium avium complex (MAC) lung disease.

Contact Information

Headquarters
1800 El Camino Real, Suite DMENLO PARK, CA, United States 94025-3069
Phone
650-331-9090
Fax
---

Executives

Chairman of the Board, Co-Founder
Joseph Zakrzewski
President, Chief Executive Officer, Co-Founder, Director
Eric Easom
Co-Founder, Head of Biology
Michael Alley
Chief Financial Officer, Treasurer, Secretary
Lucy Day
Chief Development Officer
Sanjay Chanda

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$203.3M
Revenue (TTM)
---
Shares Outstanding
19.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$3.30
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.